Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial

1. Pal, S.K.
2. Puente, J.
3. Heng, D.Y.C.
4. Glen, H.
5. Koralewski, P.
6. Stroyakovskiy, D.
7. Alekseev, B.
8. Parnis, F.
9. Castellano, D.
10. Ciuleanu, T.
11. Lee, J.L.
12. Sunela, K.
13. O'Hara, K.
14. Binder, T.A.
15. Peng, L.
16. Smith, A.D.
17. Rha, S.Y.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.EURURO.2021.12.024 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus